OBJECTIVES: As chimeric antigen receptor T cell therapies for R/R LBCL (eg, lisocabtagene maraleucel, axicabtagene ciloleucel) are being assessed by health technology assessment (HTA) bodies, health-related utility data may be required (eg, as input into cost-effectiveness models [CEMs]). Trial-generated data for health-related quality of life (HRQOL) in R/R LBCL are scarce, especially for later disease stages. This research used noninterventional time trade-off (TTO) methodology to generate health-related utility values associated with typical health states for R/R LBCL.

METHODS: This study followed the EuroQol Valuation Technology protocol for generating robust health-related utility data. Based on evidence from literature reviews and qualitative interviews with patients (n=6) and clinical experts (n=2), health state vignettes were developed reflecting the typical patient experience across different stages of R/R LBCL. Members of the United Kingdom (UK) population (n=201) valued vignettes in an online interviewer-assisted survey using the composite TTO method.

RESULTS: Three vignettes were developed capturing chronic health states: event-free survival (EFS; <2 years post treatment), prolonged EFS (≥2 years post treatment), and progression. Mean utility value for prolonged EFS was the highest (0.65), followed by EFS (0.53) and progression (0.29). Mean utility values for prolonged EFS and progression were statistically significantly different from EFS (prolonged EFS: +0.12, P<0.001; progression: −0.24, P<0.001). All utility values generated for health states associated with R/R LBCL were lower than the average HRQOL in the UK general population with similar age.

CONCLUSIONS: HRQOL in patients with R/R LBCL varies depending on disease severity, with statistically significant differences in health utilities across disease stages. Based on inputs from patients, clinical experts, and the UK general population, our health state utilities provide alternative HRQOL estimates to inform CEMs needed for HTA evaluations when HRQOL data from clinical trials across disease stages are scarce.